Press Releases

September 10, 2024 | Incendia Therapeutics Enrolls First Patient in Phase 1c Clinical Trial of PRTH-101, a Novel DDR1 Inhibitor

May 23, 2024 | Incendia Therapeutics Announces Upcoming Presentation with PathAI at the 2024 American Society of Clinical Oncology Annual Meeting

April 5, 2024 | Incendia Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research 2024

November 22, 2023 | Incendia Therapeutics to Present at 35th Annual Piper Sandler Healthcare Conference

November 13, 2023 | Incendia Therapeutics Appoints Wendye Robbins, M.D., as Chief Executive Officer and Doses First Patient in Phase 1b Clinical Trial of PRTH-101, a Novel DDR1 Inhibitor

October 31, 2023 | Incendia Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 38th Annual Meeting

October 16, 2023 | Incendia Therapeutics Announces Upcoming Presentations at the European Society for Medical Oncology Congress 2023